164 related articles for article (PubMed ID: 28001228)
21. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.
Schubach Ade O; Marzochi KB; Moreira JS; Schubach TM; Araújo ML; Vale AC; Passos SR; Marzochi MC
Rev Soc Bras Med Trop; 2005; 38(3):213-7. PubMed ID: 15895170
[TBL] [Abstract][Full Text] [Related]
22. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration.
Alkhawajah AM; Larbi E; al-Gindan Y; Abahussein A; Jain S
Ann Trop Med Parasitol; 1997 Dec; 91(8):899-905. PubMed ID: 9579209
[TBL] [Abstract][Full Text] [Related]
23. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
[TBL] [Abstract][Full Text] [Related]
24. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
[TBL] [Abstract][Full Text] [Related]
25. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
Ramalho DB; Silva RED; Senna MCR; Moreira HSA; Pedras MJ; Avelar DM; Saraiva L; Rabello A; Cota G
Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180200. PubMed ID: 29947651
[TBL] [Abstract][Full Text] [Related]
26. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
27. Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment.
Silva RED; Carvalho JP; Ramalho DB; Senna MCR; Moreira HSA; Rabello A; Cota E; Cota G
Mem Inst Oswaldo Cruz; 2018 Feb; 113(2):71-79. PubMed ID: 29236929
[TBL] [Abstract][Full Text] [Related]
28. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939
[No Abstract] [Full Text] [Related]
29. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
Costin A; Bonito F; Alves J; Barreiros H
Actas Dermosifiliogr (Engl Ed); 2020 Dec; 111(10):897-899. PubMed ID: 32473104
[No Abstract] [Full Text] [Related]
31. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
[TBL] [Abstract][Full Text] [Related]
32. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun.
Kashani MN; Sadr B; Nilforoushzadeh MA; Arasteh M; Babakoohi S; Firooz A
Int J Dermatol; 2010 Sep; 49(9):1034-7. PubMed ID: 20883265
[TBL] [Abstract][Full Text] [Related]
33. Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
Ribeiro MN; Pimentel MI; Schubach Ade O; Oliveira Rde V; Teixeira JL; Leite MP; Fonseca M; Santos GP; Salgueiro MM; Ferreira e Vasconcellos Ede C; Lyra MR; Saheki MN; Valete-Rosalino CM
Rev Inst Med Trop Sao Paulo; 2014; 56(4):291-6. PubMed ID: 25076428
[TBL] [Abstract][Full Text] [Related]
34. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
Báfica A; Oliveira F; Freitas LA; Nascimento EG; Barral A
Int J Dermatol; 2003 Mar; 42(3):203-7. PubMed ID: 12653916
[TBL] [Abstract][Full Text] [Related]
35. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
[TBL] [Abstract][Full Text] [Related]
36. Follicular mucinosis associated with cutaneous leishmaniasis.
Abajo P; Martín R; Daudén E
Acta Derm Venereol; 1998 Jul; 78(4):315. PubMed ID: 9689315
[No Abstract] [Full Text] [Related]
37. Effectiveness of intralesional meglumine antimoniate in the treatment of mucosal leishmaniasis of the Old World.
Zaraa I; Karoui S; Osman AB
J Dermatol; 2012 Feb; 39(2):201-3. PubMed ID: 21950659
[No Abstract] [Full Text] [Related]
38. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
40. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
Layegh P; Rahsepar S; Rahsepar AA
Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
